FDA extends Cadence drug review

Saying it needs more time to evaluate pharmacological data, the FDA has extended the review period for Cadence Pharmaceuticals' Acetavance until February 2010. The original PDUFA data was today. Fortunately for Cadence, the agency isn't asking for any additional data to complete its assessment of Acetavance (intravenous acetaminophen), a treatment for acute pain and fever in adults and children.

"We remain confident in our NDA submission and will continue to work closely with the FDA toward the potential approval of intravenous acetaminophen," says Ted Schroeder, President and Chief Executive Officer of Cadence. "We are now planning for a launch early in the second quarter of 2010 and continuing to move forward with all of our commercial readiness activities, including recruitment of our sales force."

- see the release from Cadence
- read the brief

Suggested Articles

A few years ago, one of our Fierce editors met a Big Pharma R&D chief for the first time. “You’re the ones with the scary name,” he joked.

Pfizer's eczema hopeful has been building its case to challenge Sanofi and Regeneron's Dupixent, but safety issues could stand in its way.

Cedrik Britten, M.D., becomes the biotech’s new chief medical officer to help run its adoptive cell therapy and TCR bispecifics platform.